719
Views
7
CrossRef citations to date
0
Altmetric
CLINICAL STUDY

Long-Term Management of Sevelamer Hydrochloride-Induced Metabolic Acidosis Aggravation and Hyperkalemia in Hemodialysis Patients

, , , &
Pages 411-418 | Published online: 07 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Makrouhi Sonikian, Evangelos Papachristou & Dimitrios S Goumenos. (2013) Optimal use of phosphate binders in chronic kidney disease. Expert Opinion on Pharmacotherapy 14:18, pages 2521-2532.
Read now

Articles from other publishers (6)

Yoshinari Oka, Masashi Miyazaki, Hiroaki Matsuda, Shigeko Takatsu, Ryouichi Katsube, Toshiko Mori, Kiyoto Takehara, Yuzo Umeda & Futoshi Uno. (2014) Sevelamer Hydrochloride Dose-Dependent Increase in Prevalence of Severe Acidosis in Hemodialysis Patients: Analysis of Nationwide Statistical Survey in Japan. Therapeutic Apheresis and Dialysis 18:1, pages 37-43.
Crossref
Zaw Thet, Aung Ko WIN, Eugenie Pedagogos, Jennifer Beavis, Sandra Crikis & Craig Nelson. (2013) Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis. BMC Nephrology 14:1.
Crossref
Amol Ramesh Mahaldar. (2012) Acid base and fluid electrolyte disturbances in Chronic Kidney Disease. Clinical Queries: Nephrology 1:4, pages 295-299.
Crossref
David B. Mount & Kambiz Zandi-Nejad. 2012. Brenner and Rector's The Kidney. Brenner and Rector's The Kidney 640 688 .
Vassilis Filiopoulos, Ioannis Koutis, Sofia Trompouki, Dimitrios Hadjiyannakos, Dimitrios Lazarou & Dimosthenis Vlassopoulos. (2011) Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 15:1, pages 20-27.
Crossref
Ashwini B. Pai & Brian M. Shepler. (2012) Comparison of Sevelamer Hydrochloride and Sevelamer Carbonate: Risk of Metabolic Acidosis and Clinical Implications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:5, pages 554-561.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.